Mergers & AcquisitionsMedium•6 November 2026•
1 min read
Lifecore Biomedical Clears Key Regulatory Hurdle for Merger Completion
Key Facts
1Lifecore Biomedical announced the expiration of the Hart-Scott-Rodino (HSR) Act waiting period for its proposed merger.
Lifecore Biomedical announced the expiration of the Hart-Scott-Rodino (HSR) Act waiting period for its proposed merger. Benzinga reported that clearing this federal waiting period without objection satisfies a critical regulatory requirement for the completion of the corporate transaction.
LFCR closed at $6.4 on November 5, 2026, with the stock reaching a day high of $6.45 and a low of $6.38 during that session. The regulatory clearance is a significant milestone for the merger's progress, although specific details regarding the acquirer were not highlighted in the announcement.